TUMOR NECROSIS FACTOR (TNF) BLOCKER
Eticovo is a prescription drug approved by the U.S Food and Drug Administration (FDA) to treat rheumatoid arthritis. It is also indicated to treat polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. Eticovo is also referred to by its drug name, etanercept-ykro.
Eticovo is a biologic therapy for rheumatoid arthritis. Eticovo is a member of a class of drugs called tumor necrosis factor (TNF) blockers. Eticovo is believed to work by binding to and inhibiting TNF-alpha, reducing the normal functions of TNF including inflammation and immune response.
How do I take it?
Prescribing information states that Eticovo is administered via injection once weekly with or without methotrexate.
Eticovo comes as the form of a subcutaneous injection.
The FDA-approved label for Eticovo lists common side effects including infections (such as upper respiratory infections, nasopharyngitis, sinusitis, and influenza) and injection site reactions.
Rare but serious side effects listed for Eticovo include lupus-like syndrome, autoimmune hepatitis, serious allergic reactions, anemia (low red blood counts), congestive heart failure, demyelinating disease (such as multiple sclerosis), lymphoma, and serious infections.
For more details about this treatment, visit:
Eticovo — RxList